Bayer AG reported positive results for elinzanetant in women with or at high risk of a type of breast cancer, broadening the ...
Announcing topline data from its OASIS 4 Phase 3 study, the German conglomerate said that its non-hormonal treatment option ...
Vasomotor symptoms are a common problem in women with HR-positive breast cancer receiving anti-cancer therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback